查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466251

白斑症治疗药物市场：治疗方法、疾病类型、药物类型、最终用户、分销管道 - 全球预测 2024-2030

Vitiligo Therapeutics Market by Treatment (Light Therapy, Surgical Procedures, Topical Treatment), Disease Type (Nonsegmental Vitiligo, Segmental Vitiligo), Drug Type, End User, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年白斑症治疗药物市场规模为14.5亿美元，预计2024年将达15.6亿美元，2030年将达25.5亿美元，复合年增长率为8.43%。

白斑症治疗包括各种旨在控制和改善白斑症的医学治疗和策略，白斑症是一种由于黑色素细胞（负责皮肤色素的细胞）丧失而导致皮肤上出现白斑的疾病。该医疗领域包括局部和全身干预、先进的照光治疗、外科手术和心理支持。这些治疗方法的主要目标是稳定病情、促进色素沉淀并改善白斑症患者的生活品质。随着寻常性白斑症盛行率的增加，对改进的白斑症治疗药物的需求增加，从而促进了市场的成长。创新治疗方法、持续研究以及更有效治疗方法的开发正在推动市场扩张。公共和私营部门不断增长的全球医疗保健支出正在推动更强劲的市场开拓。然而，与先进治疗方法相关的高成本可能会阻碍白斑症治疗方法进入市场。在某些地区，对白斑的了解和认识有限阻碍了其诊断和治疗。此外， Janus激酶 (JAK) 抑制剂等标靶治疗的进展为治疗包括白斑症在内的自体免疫疾病提供了潜在的机会。在遗传和生物标记研究的支持下，增加对联合治疗和个人化医疗的研发投资预计也将在未来几年带来市场成长的潜力。

主要市场统计
基准年[2023] 14.5亿美元
预测年份 [2024] 15.6亿美元
预测年份 [2030] 25.5亿美元
复合年增长率（%） 8.43%

治疗性光疗法的重大技术进步

照光治疗，例如 UVB照光治疗或 PUVA（补骨脂素 + UVA）疗法，是白斑症的常见治疗方法，包括在医生的监督下将皮肤暴露在紫外线 (UV) 下。照光治疗适合白斑症影响身体大部分部位或局部治疗效果不够有效的患者。手术治疗包括植皮、微色素沉着和黑色素细胞移植，以控制稳定的长效白斑。皮肤移植涉及将皮肤的色素区域移植到脱色斑块上，黑色素细胞移植涉及将健康皮肤的黑色素细胞移植到受影响的区域。局部治疗包括将乳霜或软膏直接涂布在皮肤上。局部治疗包括皮质类固醇、Calcineurin抑制剂和其他促进或预防色素沉着的药物。局部治疗最适合患有小型、局限性白斑症的患者，并且通常建议用于不适合照光治疗或手术治疗的敏感区域的白斑患者。

节段性白斑疾病类型的盛行率增加

非节段性白斑症是最常见的形式，有多种治疗选择，包括局部用药、照光治疗、全身治疗和手术。非节段性白斑通常是进行性的，治疗方法旨在阻止进展、实现色素沉着并提供持久的效果。节段性白斑较为局限，往往是只影响身体一侧的局限性白斑。节段性白斑症一般起病较快，通常在几年内稳定下来，治疗方法通常包括早期疗育和标靶治疗。

药物类型 JAK 抑制剂在白斑症治疗中具有良好的治疗作用

Calcineurin抑制剂，包括Tacrolimus和Pimecrolimus，是局部免疫调节剂，越来越多地用于治疗白斑症，特别是在对类固醇敏感的区域，例如脸部和颈部。Calcineurin酶抑制剂透过抑制Calcineurin发挥作用，从而降低皮肤中 T 细胞的活性，并可能导致色素脱失。对于寻求节省类固醇选择或色素脱失较小且局部的患者来说，Calcineurin抑制剂是首选。Calcipotriene(Calcipotriene) 是一种合成维生素 D3 类似物，可促进黑色素细胞增殖并促进皮肤色素沉着。皮质类固醇经常用于治疗白斑症，以减少发炎并阻止疾病的进展。皮质类固醇有外用、口服和注射形式，适用于更广泛的脱色。 JAK抑制剂是一种针对Janus激酶（JAK）途径的治疗白斑症的新型药物，该路径在白斑的发病机制中发挥重要作用。託法替尼和鲁索替尼等 JAK 抑制剂在临床试验中在诱导色素沉着过度方面显示出有希望的结果。由于 JAK 抑制剂可以口服给药，因此它们可能是更广泛的白斑症全身治疗的一种选择。

最终使用者：由于成本效益，对皮肤诊所的偏好增加

能够提供综合护理和先进治疗方案的医院在白斑药物市场中占有很大份额。医院拥有专门的皮肤科，拥有最先进的技术和执行复杂白斑症治疗的专家团队。皮肤诊所专注于皮肤病治疗，通常提供个人化服务，这对寻求有针对性的白斑症治疗的患者很有吸引力。透过专注于门诊治疗并尽量减少侵入性手术，皮肤诊所比医院更方便且更具成本效益。

分销通路：网路药局通路呈现成长趋势

白斑症治疗药物的主要分销管道是医院药房，患者在咨询和治疗后可以立即直接获得处方药。医院药局的选择取决于需要，特别是为了方便在皮肤科手术或与白斑症相关的医院治疗后立即获得药物。网路药局由于购买药品的便利性和隐私性，已成为白斑症治疗药物的重要通路。与实体药局相比，由于管理成本较低，线上药局也提供有竞争力的价格。零售药局是分销白斑症治疗药物的传统且普及的管道。零售药局通常是首选，因为它们可以随时获得非处方药和个人化服务。

区域洞察

在美国，白斑症的盛行率不断上升，导致白斑症治疗的消费者基础不断扩大。主要製药公司的存在和强大的医疗保健基础设施正在支持美洲地区的市场扩张。欧盟 (EU) 是一个提供多种白斑症治疗和先进治疗解决方案的市场。欧洲研究经费的增加有助于扩大白斑症治疗的管道。由于不同的经济条件、医疗基础设施和对白斑的文化认知，中东和非洲市场非常复杂。由于意识的提高、医疗保健系统的改善和可支配收入的增加，亚太地区正在见证巨大的成长潜力。亚太地区的参与者正在与全球相关人员合作，以提高对开拓区域市场的渗透率，从而推动亚太地区的市场成长。

FPNV定位矩阵

FPNV定位矩阵对于评估白斑症治疗药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对白斑症治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.白斑症治疗药物市场规模及预测如何？

2.白斑症治疗药物市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.白斑症治疗药物市场的技术趋势和法规结构是什么？

4.白斑症治疗药物市场主要供应商的市场占有率为何？

5.进入白斑症治疗药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球白斑症病例不断增加
      • 提高人们对有效治疗方法的认识
    • 抑制因素
      • 白斑症治疗和产品召回的潜在风险
    • 机会
      • 增加临床试验和研发活动，有效开发白斑治疗药物
      • 白斑症治疗药物的有利报销方案
    • 任务
      • 发展中地区的治疗方法有限，且有与白斑药物相关的副作用风险。
  • 市场区隔分析
    • 治疗：光疗的重大技术进步
    • 疾病类型：节段性白斑症盛行率上升
    • 药物类型：JAK抑制剂治疗白斑效果良好
    • 最终用户：由于成本效益，在皮肤科诊所中越来越受欢迎
    • 分销通路：网路药局通路呈现成长趋势
  • 市场趋势分析
    • 白斑拥有强大的研发基础设施，并且正在美洲进行临床试验以发现新的治疗方法。
    • 认识宣传活动和治疗组合的改进导致先进的白斑症治疗在亚太地区获得核准
    • 欧洲、中东和非洲地区的白斑症盛行率不断上升，增加了对新治疗方法的需求
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章 依治疗分類的白斑症治疗药物市场

  • 光疗
  • 手术过程
  • 局部治疗

第七章白斑症治疗药物市场：依疾病类型

  • 非节段性白斑
  • 节段性白斑

第八章白斑症治疗药物市场依药物类型划分

  • Calcineurin抑制剂
  • Calcipotriene
  • 皮质类固醇
  • JAK抑制剂

第九章白斑症治疗药物市场：依最终用户分类

  • 医院
  • 皮肤科诊所

第10章白斑症治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 北美、南美白斑症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区白斑症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲白斑症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Clinuvel 开始白斑第三阶段国际研究
    • 艾伯维 (AbbVie) 宣布Upadacitinib(Rinvoc) 在白斑症 2 期临床试验中达到主要终点，并将计画推进至 3 期
    • Glenmark Pharmaceuticals 0.03%Tacrolimus软膏获得 sANDA核准
    • AVITA Medical 宣布 FDA核准RECELL 用于白斑症患者的皮肤色素沉着治疗
    • Insight 宣布欧盟委员会核准Opzella (Ruxolitinib) 霜用于治疗成人和青少年面部非节段性白斑
    • 麻省理工学院陈学院 (MIT Chan College) 向 Ardena Therapeutics 授予 siRNA 化学许可，用于开发皮肤病治疗方法
    • 加拿大卫生署核准Edesa Biotech 的白斑症治疗试验
    • Ahamne Biosciences 完成白斑症治疗第一期临床试验
    • Insight 宣布与 Medixie 支持的 Viralis Therapeutics 就抗 IL-15RB 单株抗体 Auremolimab (VM6) 达成收购协议
    • Almirall 和 Inselm Transfer 签署白斑症调查合约

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-742BD51851D2

[183 Pages Report] The Vitiligo Therapeutics Market size was estimated at USD 1.45 billion in 2023 and expected to reach USD 1.56 billion in 2024, at a CAGR 8.43% to reach USD 2.55 billion by 2030.

Vitiligo therapeutics encompasses a range of medical treatments and strategies aimed at managing and remedying vitiligo, a condition characterized by the development of white patches on the skin due to the loss of melanocytes, the cells responsible for skin pigment. This field of medicine includes both topical and systemic interventions, advanced light-based therapies, surgical procedures, and psychological support. The primary goals of these therapeutic approaches are to stabilize the condition, encourage repigmentation, and improve the quality of life for individuals affected by vitiligo. The rising prevalence of vitiligo conditions is enhancing the need for improved vitiligo therapeutics, contributing to the market growth. Innovative therapies, ongoing research, and developments in more effective treatments fuel market expansion. The higher healthcare spending worldwide by the public and private sectors empowers more robust market development. However, high costs associated with advanced therapeutics may hinder the market accessibility of vitiligo therapies. Limited understanding and awareness of vitiligo in certain geographical regions impede diagnosis and treatment of vitiligo. Moreover, the advancements in targeted therapies, such as Janus kinase (JAK) inhibitors, show potential opportunities in treating autoimmune disorders, including vitiligo. The increased investment in R&D for combination therapies and personalized medicine, underpinned by genetic and biomarker studies, is also anticipated to present the potential for market growth in upcoming years.

KEY MARKET STATISTICS
Base Year [2023] USD 1.45 billion
Estimated Year [2024] USD 1.56 billion
Forecast Year [2030] USD 2.55 billion
CAGR (%) 8.43%

Treatment: Significant technological advancements in light therapies

Light therapy such as UVB phototherapy and PUVA (psoralen plus UVA) therapy are common treatments for vitiligo, which involves exposing the skin to ultraviolet (UV) light under medical supervision. Light therapies are preferred for patients with significant portions of their body afflicted with vitiligo or those who have not responded adequately to topical treatments. Surgical procedures include skin grafting, micro pigmentation, and melanocyte transplantation to manage stable and long-acting vitiligo disorder. Skin grafting involves transferring skin from pigmented areas to depigmented patches, whereas melanocyte transplantation involves transferring melanocytes from healthy skin to the affected areas. Topical treatment constitutes creams and ointments applied directly to the skin. Topical treatment includes corticosteroids, calcineurin inhibitors, and other agents to promote pigmentation or stop depigmentation. Topical treatments are most suitable for patients with small, localized patches of vitiligo and are often recommended for those with the disease affecting sensitive areas that may not be ideal for light therapy or surgical options.

Disease Type: Rising prevalence of segmental vitiligo disorder

Nonsegmental vitiligo is the most common form, with broad treatment options, including topical agents, phototherapy, systemic treatments, and surgical options. Nonsegmental vitiligo is often progressive, and treatment approaches aim to halt progression, achieve repigmentation, and offer sustainable results. Segmental vitiligo tends to be more localized and sectorial, impacting only one side of the body. Segmental vitiligo typically has an earlier onset and often stabilizes within a few years, with the treatment approach commonly involving early intervention with targeted therapies.

Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management

Calcineurin inhibitors, including tacrolimus and pimecrolimus, are topical immunomodulators that have been increasingly used for treating vitiligo, especially for areas sensitive to steroid effects, such as the face and neck. Calcineurin inhibitors act by inhibiting calcineurin, which subsequently reduces the activity of T-cells in the skin and can cause pigment loss. Calcineurin inhibitor drugs are a preferred option for patients looking for steroid-sparing alternatives and for those with smaller, localized areas of depigmentation. Calcipotriene, a synthetic vitamin D3 analogue, promotes melanocyte multiplication and enhances skin repigmentation. Corticosteroids are frequently prescribed in the treatment of vitiligo to reduce inflammation and to attempt to halt the progression of the disease. Corticosteroids are available in topical, oral, and injectable forms and are suited for more widespread areas of pigment loss. JAK inhibitors represent a newer class of drug in vitiligo management that targets the Janus kinase (JAK) pathway, which is crucial in the pathogenesis of vitiligo. JAK inhibitors, such as tofacitinib and ruxolitinib, have shown promising results in clinical trials for inducing repigmentation. Due to their oral route of administration, JAK inhibitors could offer a systemic treatment option for more extensive vitiligo.

End User: Growing preference for skin clinics due to cost effectiveness

Hospitals hold a substantial share in the vitiligo therapeutics market due to their ability to offer comprehensive care and advanced treatment options. Hospitals have specialized dermatology departments equipped with cutting-edge technologies and a team of experts to administer complex vitiligo treatments. Skin clinics specialize in dermatological care and often offer personalized services, which make them appealing for patients seeking targeted vitiligo treatment. Skin clinics provide improved accessibility and cost-effectiveness than hospital settings, focusing on outpatient care and minimal use of invasive procedures.

Distribution Channel: Rising inclination towards online pharmacy channels

Hospital pharmacies represent a primary distribution channel for vitiligo therapeutics where patients have direct access to prescribed medications immediately after consultation or treatment. The need-based preference for hospital pharmacies stems from the convenience of immediate access to medication, especially after dermatological procedures or inpatient care related to vitiligo. Online pharmacies have become important as a distribution channel for vitiligo therapeutics due to the convenience and privacy of medicine purchases. Online pharmacies also provide competitive pricing due to lower overhead costs compared to brick-and-mortar pharmacies. Retail pharmacies remain a traditional and widespread channel for distributing vitiligo therapeutics. The preference for retail pharmacies is often due to the immediate availability of over-the-counter treatments and personalized service.

Regional Insights

In the Americas region, the United States has observed a substantial consumer base for vitiligo therapeutics due to the rising prevalence of vitiligo disease. The presence of key pharmaceutical companies and robust healthcare infrastructure propels the market forward in the Americas region. The European Union presents a diverse market with varying access to vitiligo treatments and advanced therapeutic solutions. The increased research funding within the European region has contributed to a growing pipeline of vitiligo therapies. The Middle East and Africa markets are complex due to the variation in economic status, healthcare infrastructure, and cultural perceptions of vitiligo. The Asia-Pacific region has witnessed significant growth potential due to increasing awareness, improving healthcare systems, and rising disposable incomes. The players in the APAC region are collaborating with global stakeholders to enhance the market penetration into untapped regional markets, driving market growth in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vitiligo Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vitiligo Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vitiligo Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accord Healthcare, Inc., Ahammune Biosciences Pvt. Ltd., Amgen Inc., Arcutis Biotherapeutics, Inc., Array Skin Therapy, Astellas Pharma, Inc., AVITA Medical, Inc., Bausch Health Companies Inc., Biocon Limited, Clarify Health Solutions, Inc., Clinuvel Pharmaceuticals Ltd., Dermavant Sciences, Inc., Dr. Reddy's Laboratories Ltd., Edesa Biotech, Inc., Glenmark Pharmaceuticals Limited, Incyte Corporation, ISSAR pharmaceuticals Pvt. Ltd., JN Biosciences LLC, Kernel Medical Equipment Co.,LTD, Koninklijke Philips N.V., Merck KGaA, Mylan N.V. by Viatris Inc., Nova Dermatology, Novartis AG, Organic Care Australia Pty Ltd., Panacea Biotec Limited, Pfizer Inc., Philadelphia Pharmaceuticals, Pierre Fabre S.A, Puneet Laboratories Pvt. Ltd., SESDERMA, S.L, SOMA Skin & Laser, LLC, Stem Cell Care India, Strides Pharma Science Limited, Temprian Therapeutics Inc., TeVido BioDevices, The Daavlin Company, UNIZA Group, and Vyne Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Vitiligo Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Light Therapy
    • Surgical Procedures
      • Cell Transplant
      • Skin Graft
    • Topical Treatment
  • Disease Type
    • Nonsegmental Vitiligo
    • Segmental Vitiligo
  • Drug Type
    • Calcineurin Inhibitors
    • Calcipotriene
    • Corticosteroids
    • JAK inhibitor
  • End User
    • Hospitals
    • Skin Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vitiligo Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vitiligo Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Vitiligo Therapeutics Market?

4. What is the market share of the leading vendors in the Vitiligo Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Vitiligo Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases of vitiligo across the globe
      • 5.1.1.2. Growing awareness regarding the availability of effective treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of vitiligo drug and product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
      • 5.1.3.2. Favorable reimbursement scenario for vitiligo therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Significant technological advancements in light therapies
    • 5.2.2. Disease Type: Rising prevalence of segmental vitiligo disorder
    • 5.2.3. Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management
    • 5.2.4. End User: Growing preference for skin clinics due to cost effectiveness
    • 5.2.5. Distribution Channel: Rising inclination towards online pharmacy channels
  • 5.3. Market Trend Analysis
    • 5.3.1. Strong research and development infrastructure for vitiligo with clinical trials underway to discover new treatment modalities in the Americas
    • 5.3.2. Approvals for advanced vitiligo therapeutics in APAC backed by improved awareness campaigns and therapeutics portfolios
    • 5.3.3. Elevating prevalence of vitiligo creating need for novel therapeutics in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Vitiligo Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Light Therapy
  • 6.3. Surgical Procedures
  • 6.4. Topical Treatment

7. Vitiligo Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Nonsegmental Vitiligo
  • 7.3. Segmental Vitiligo

8. Vitiligo Therapeutics Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Calcineurin Inhibitors
  • 8.3. Calcipotriene
  • 8.4. Corticosteroids
  • 8.5. JAK inhibitor

9. Vitiligo Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Skin Clinics

10. Vitiligo Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Vitiligo Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vitiligo Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vitiligo Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinuvel Starts Global Phase III Vitiligo Study
    • 14.3.2. AbbVie Announces Upadacitinib (RINVOQ) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
    • 14.3.3. Glenmark Pharmaceuticals Receives sANDA Approval for Tacrolimus Ointment, 0.03%
    • 14.3.4. AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
    • 14.3.5. Incyte Announces European Commission Approval Of Opzelura (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
    • 14.3.6. UMass Chan Licensed siRNA chemistry to Aldena Therapeutics To Develop Therapies For Dermatological Diseases
    • 14.3.7. Health Canada Grants Approval for Edesa Biotech's Vitiligo Therapy Trial
    • 14.3.8. Ahammune Biosciences Completes Phase I Clinical Trial For Vitiligo Drug
    • 14.3.9. Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (VM6), An Anti-IL-15RB Monoclonal Antibody
    • 14.3.10. Almirall, Inserm Transfert Enter Agreement for Vitiligo Research

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VITILIGO THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VITILIGO THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VITILIGO THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VITILIGO THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 167. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 168. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 169. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 180. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 181. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 190. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 191. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 192. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 193. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 204. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 205. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 214. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 216. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 226. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 227. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 228. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 229. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 238. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 250. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 251. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 252. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 253. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 262. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 263. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 264. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 265. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 274. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 275. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 276. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 277. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 299. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 302. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 303. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 310. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 311. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 312. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 313. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 314. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 315. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 320. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 321. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 324. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 325. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 326. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 327. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 332. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 333. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 334. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 335. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 336. FRANCE